CL2015002466A1 - Formulaciones de compuestos orgánicos - Google Patents

Formulaciones de compuestos orgánicos

Info

Publication number
CL2015002466A1
CL2015002466A1 CL2015002466A CL2015002466A CL2015002466A1 CL 2015002466 A1 CL2015002466 A1 CL 2015002466A1 CL 2015002466 A CL2015002466 A CL 2015002466A CL 2015002466 A CL2015002466 A CL 2015002466A CL 2015002466 A1 CL2015002466 A1 CL 2015002466A1
Authority
CL
Chile
Prior art keywords
organic compound
compound formulations
invention refers
sterylphumarate
phosfatidylinositol
Prior art date
Application number
CL2015002466A
Other languages
English (en)
Inventor
Charu Kochhar
Jacques Quinton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2015002466A1 publication Critical patent/CL2015002466A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12136—Balloons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027—Type of occlusion
    • A61B17/1204—Type of occlusion temporary occlusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1002—Balloon catheters characterised by balloon shape
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205—Introduction devices
    • A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12068—Details concerning the detachment of the occluding device from the introduction device detachable by heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205—Introduction devices
    • A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12086—Details concerning the detachment of the occluding device from the introduction device magnetically detachable

Abstract

LA PRESCNTE INVENCIÓN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN EL COMPUESTO INHIBIDOR DE LA FOSFATIDILINOSITOL 3-QUINASA 4-(TRIFLUOROMETIL)-5-(2,6-DIMORIOLINOPIRIMIDIN-4-IL) PIRIDIN-2-AMINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, ESTEARILFUMARATO DE SODIO, Y OPCIONALMENTE AL MENOS UN VEHICULO FARMACÉUTICAMENTE ACEPTABLE ADICIONAL. LA PRESENTE INVENCION SE REFIERE TAMBIEN A LOS PROCESOS PARA SU PREPARACIÓN Y A SU USO COMO MEDICAMENTOS PARA EL TRATAMIENTO DEL CANCER.
CL2015002466A 2013-03-06 2015-09-04 Formulaciones de compuestos orgánicos CL2015002466A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361773492P 2013-03-06 2013-03-06

Publications (1)

Publication Number Publication Date
CL2015002466A1 true CL2015002466A1 (es) 2016-03-04

Family

ID=50342366

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002466A CL2015002466A1 (es) 2013-03-06 2015-09-04 Formulaciones de compuestos orgánicos

Country Status (29)

Country Link
US (2) US9474534B2 (es)
EP (1) EP2964200B1 (es)
JP (1) JP6313343B2 (es)
KR (1) KR102233757B1 (es)
CN (1) CN105073099B (es)
AR (1) AR095032A1 (es)
AU (1) AU2014224238B2 (es)
BR (1) BR112015021097B1 (es)
CA (1) CA2904032C (es)
CL (1) CL2015002466A1 (es)
EA (1) EA028301B1 (es)
ES (1) ES2634020T3 (es)
HK (1) HK1212244A1 (es)
IL (1) IL240579B (es)
JO (1) JO3256B1 (es)
MA (1) MA38358B1 (es)
MX (1) MX370175B (es)
MY (1) MY174648A (es)
NZ (1) NZ711015A (es)
PE (1) PE20151607A1 (es)
PH (1) PH12015501945B1 (es)
PL (1) PL2964200T3 (es)
PT (1) PT2964200T (es)
SG (1) SG11201506392VA (es)
TN (1) TN2015000386A1 (es)
TW (1) TW201442712A (es)
UA (1) UA114948C2 (es)
WO (1) WO2014136048A1 (es)
ZA (1) ZA201505830B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498604B2 (en) 1997-11-12 2016-11-22 Genesis Technologies Llc Medical device and method
US9561094B2 (en) 2010-07-23 2017-02-07 Nfinium Vascular Technologies, Llc Devices and methods for treating venous diseases
CN105792879A (zh) 2014-06-04 2016-07-20 恩菲纽姆血管技术有限公司 低径向力血管设备和闭塞方法
HRP20240045T1 (hr) * 2015-06-30 2024-03-29 Genentech, Inc. Tablete s trenutnim oslobađanjem koje sadrže lijek i postupci za proizvodnju tableta
US20220096094A1 (en) * 2020-09-27 2022-03-31 Boston Scientific Scimed, Inc. Expandable guide devices, systems, and methods
US20220249813A1 (en) * 2021-02-05 2022-08-11 Devaraj Pyne Detachable balloon embolization device and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU713849B2 (en) * 1995-12-27 1999-12-09 Janssen Sciences Ireland Uc Bioadhesive solid dosage form
US5916235A (en) 1997-08-13 1999-06-29 The Regents Of The University Of California Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities
DE69941894D1 (de) * 1998-02-10 2010-02-25 Artemis Medical Inc Okklusions-, verankerungs-, span- oder stromsteuergerät
US6066157A (en) 1998-09-16 2000-05-23 Medtronics Ave, Inc. Anchor joint for coaxial balloon dilatation catheter
US6368338B1 (en) 1999-03-05 2002-04-09 Board Of Regents, The University Of Texas Occlusion method and apparatus
US7331973B2 (en) 2002-09-30 2008-02-19 Avdanced Cardiovascular Systems, Inc. Guide wire with embolic filtering attachment
US7618435B2 (en) * 2003-03-04 2009-11-17 Nmt Medical, Inc. Magnetic attachment systems
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2010027921A1 (en) * 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
AU2010308433A1 (en) * 2009-10-23 2012-06-07 Merck Sharp & Dohme Corp. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
US8992540B2 (en) 2010-07-22 2015-03-31 Kyphon Sarl Adjustable surgical instruments and methods of use and fabrication
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012166804A1 (en) 2011-06-03 2012-12-06 Reverse Medical Corporation Embolic implant and method of use
WO2014164535A1 (en) 2013-03-11 2014-10-09 Ferry Steven J A guidewire/ partial occluder for intraluminal travel

Also Published As

Publication number Publication date
UA114948C2 (uk) 2017-08-28
NZ711015A (en) 2020-02-28
AR095032A1 (es) 2015-09-16
MX2015011705A (es) 2016-05-18
PH12015501945A1 (en) 2016-01-11
CA2904032A1 (en) 2014-09-12
PL2964200T3 (pl) 2017-09-29
JP6313343B2 (ja) 2018-04-18
IL240579A0 (en) 2015-09-24
MX370175B (es) 2019-12-04
AU2014224238B2 (en) 2016-07-14
KR102233757B1 (ko) 2021-03-30
ZA201505830B (en) 2017-07-26
JP2016510065A (ja) 2016-04-04
CA2904032C (en) 2021-02-16
AU2014224238A1 (en) 2015-09-03
KR20150123248A (ko) 2015-11-03
MA38358A1 (fr) 2016-11-30
BR112015021097B1 (pt) 2022-08-30
MY174648A (en) 2020-05-05
US9474534B2 (en) 2016-10-25
ES2634020T3 (es) 2017-09-26
TN2015000386A1 (en) 2017-01-03
CN105073099B (zh) 2018-10-26
WO2014136048A1 (en) 2014-09-12
US10342547B2 (en) 2019-07-09
MA38358B1 (fr) 2017-07-31
US20160045202A1 (en) 2016-02-18
TW201442712A (zh) 2014-11-16
JO3256B1 (ar) 2018-09-16
US20160015643A1 (en) 2016-01-21
HK1212244A1 (en) 2016-06-10
SG11201506392VA (en) 2015-09-29
CN105073099A (zh) 2015-11-18
PH12015501945B1 (en) 2016-01-11
EP2964200B1 (en) 2017-04-19
PT2964200T (pt) 2017-07-25
PE20151607A1 (es) 2015-11-26
EA201591649A1 (ru) 2016-01-29
EP2964200A1 (en) 2016-01-13
BR112015021097A2 (pt) 2017-07-18
EA028301B1 (ru) 2017-10-31
IL240579B (en) 2019-08-29

Similar Documents

Publication Publication Date Title
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
PE20151067A1 (es) Inhibidores de autotaxina
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
GT201400111A (es) Triazolopiridinas sustituidas
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CR20180232A (es) Macrociclos peptídicos contra acinetobacter baumannii
GT201500021A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
GT201200334A (es) Morfolinopirimidinas y su uso en terapia
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CU20150071A7 (es) Composición de liberación demorada que comprende biguanida
GT201500247A (es) Imidazopiridazinas sustituidas
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2